Article
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
International journal of cancer - 15 Nov 2009
He Chen, Liu Ming, Zhou Chengzhi, Zhang Jiexia, Ouyang Ming, Zhong Nanshan, Xu Jun
Abstract excerpt
The high frequency of epidermal growth factor receptor (EGFR) mutations in tyrosine kinase inhibitor-responsive non-small-cell lung cancer (NSCLC) cases is now well established, highlighting the predictive value of activating EGFR mutations in guiding the clinical use of EGFR-targeted therapies....
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Large Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- DNA, Neoplasm
- ErbB Receptors
- Female
- Gefitinib
- Humans
- Lung Neoplasms
- Male